
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Click the title above to open the Pharmaceutical Technology January 2014 issue in an interactive PDF format.
over 12 years ago
UK Biotech Gains Momentumalmost 13 years ago
Drugs, At What Cost?almost 13 years ago
CS Inspection Machine Improves Efficiencyalmost 13 years ago
Ribbon Blender Model 42N-270 Increases Performancealmost 13 years ago
Innovation and Market Growth in Brazilalmost 13 years ago
R&D in Transitionalmost 13 years ago
ALpHA G Capsule Filter for Single-Use Systemsalmost 13 years ago
Battling Off-Weight Tabletsalmost 13 years ago
Metrics Sought to Ensure Drug Qualityalmost 13 years ago
Gericke N200 Nibbler Provides Size Reduction




